171 results about "Premalignant Neoplasm" patented technology

KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.

Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.

This invention provides the application of Jiawei Xihuang Pill (MXHP) in the preparation of drugs for the prevention and / or treatment of malignant tumors. This invention also provides the application of Jiawei Xihuang Pill in combination with chemotherapy drugs for the prevention and / or treatment of malignant tumors, particularly glioblastoma multiforme (GBM), wherein the active ingredients of Jiawei Xihuang Pill are prepared from bezoar, musk, vinegar-processed frankincense, vinegar-processed myrrh, and Panax notoginseng root extract in a weight ratio of 14-16:14-16:545-555:545-555:245-255. MXHP can synergistically inhibit the growth of glioblastoma in situ and induce tumor cell apoptosis, indicating that MXHP may be a potential therapeutic drug. Furthermore, compared to XHP, MXHP significantly prolongs the median survival of GBM, exhibiting an enhanced anti-GBM effect.

The invention belongs to the field of molecular biology, particularly relates to the field of tumor treatment, and particularly relates to application of a TRK inhibitor LYS-8 in preparation of a medicine for treating malignant tumors, particularly pancreatic cancer. LYS-8 is a small molecule TRK inhibitor with a novel structure, and research finds that LYS-8 can significantly inhibit TRK kinase activity and down-regulate downstream PI3K-AKT and other signal channels. Experimental results show that the inhibition effect of LYS-8 in pancreatic cancer cells is obviously superior to that of colorectal cancer cells, and the IC50 value of LYS-8 is lower; in an animal model, the tumor inhibition rate of LYS-8 on pancreatic cancer reaches about 70%, and the inhibition rate on colorectal cancer is about 56%, which is obviously superior to that of a colorectal cancer model. The invention reveals that LYS-8 has an unexpected curative effect advantage on pancreatic cancer, and a new drug choice is provided for targeted therapy of pancreatic cancer.

The disclosure belongs to the technical field of medicine. Provided are a CD97 and GSDME interaction inhibitor having anti-tumor activity and an application thereof. A compound screened in the disclosure enhances the susceptibility of NK cells to kill tumor cells by inhibiting the interaction between GSDME and CD97 in tumor cells, so as to induce an immune anti-tumor effect. Moreover, the compound enhances the susceptibility of tumor cells to pyroptosis by blocking the protective effect of CD97 on cleavage of GSDME proteins. Therefore, the compound can be used for treating GSDME and CD97 double-positive malignant tumors, and combined chemotherapy, immunotherapy, etc., to enhance the susceptibility of malignant tumors to chemotherapy and immunotherapy, prolonging the overall survival period of patients with malignant tumors. Specifically provided is a compound having a structure set forth in formula (I), a pharmaceutically acceptable salt, a solvent compound or a deuterated compound thereof.

This invention discloses a PROTAC chimera for targeted degradation of ALKBH5, its preparation method, and its applications. The structural formula of the PROTAC chimera is shown in Formula I. The PROTAC chimera provided by this invention achieves specific ubiquitination modification and proteasome-dependent degradation of the ALKBH5 protein, completely eliminating the target protein function from its source. This invention overcomes the inherent limitations of traditional small molecule inhibitors, which can only reversibly block ALKBH5 enzyme activity, cannot eliminate the target protein, easily induce compensatory upregulation of the target protein, and develop drug resistance. It provides a novel and precise targeted therapy strategy for ALKBH5-driven malignant tumors.

The invention relates to a medical instrument for gynecologic operation, in particular to a uterus traction device capable of avoiding tumor cell diffusion and a using method thereof.The traction device comprises a bag, the bag is provided with a closed end used for wrapping the bottom of the uterus and an open end used for facing the cervix uteri opening, and the bag is provided with an opening. The open end is provided with an adjusting and tightening mechanism, the cervix uteri, the uterus body and the double accessories of the cervix uteri and the uterus body can be wrapped in the bag by pulling the open end, and then the open end is tightened through the adjusting and tightening mechanism. A wrapping path in the direction from the bottom of the uterus to the cervix uteri opening is adopted, it is ensured that the uterus and contents of the uterus are completely wrapped and isolated in the bag by tightening the opening end, the operation concept that isolation is carried out in advance is achieved, the operation view is protected in the whole process, and tumor-free traction in the operation process is facilitated; in addition, the risks of incision planting and abdominal cavity spreading in malignant tumor surgery can be greatly reduced, the possibility of tumor cell spreading is avoided, and iatrogenic injury is reduced.

To provide a therapeutic agent enabling treatment of a malignant tumor.SOLUTION: A therapeutic agent comprising a substance that recognizes a target expressed in an erythroblast, where the therapeutic agent is administered such that, during a dosing period, a serum concentration of the substance in a subject administered with the therapeutic agent is maintained at 10% or more of a maximum value after administration.SELECTED DRAWING: None

The present invention belongs to the technical field of medicine, and specifically relates to the use of a compound as represented by the following formula (I) or a pharmaceutically acceptable salt, isomer, or crystal form thereof in the preparation of a drug for preventing or treating malignant B cell tumors.

The invention relates to the technical field of biological medicines, and particularly discloses siRNA for inhibiting CD44v6 expression in tumors and application of the siRNA. The siRNA molecule can specifically target mRNA of CD44v6, and efficient knock-down is achieved on the gene level and the protein level (the interference efficiency reaches 70%-90%); in-vitro experiments prove that the siRNA can significantly inhibit the proliferation ability and clone formation ability of gastric cancer cells (such as AGS and HGC-27); in-vivo and in-vitro experiments further show that the siRNA can enhance the sensitivity of gastric cancer cells to a ferroptosis inducer RSL3 and generate a synergistic anti-tumor effect. The invention further provides a pharmaceutical composition containing the siRNA and application of the pharmaceutical composition in preparation of drugs for treating malignant tumors such as gastric cancer, and a new strategy and means are provided for overcoming the problem that tumor progression is fast.

This invention discloses a radioactive molecular probe for targeting CSPG4 / NG2, its preparation method, and its application. The radioactive molecular probe comprises the structure shown in Formula I or Formula II. The technical solution of this invention uses a radioactive molecular probe to specifically recognize CSPG4 / NG2 in vivo through the target polypeptide portion, thereby achieving specific nuclear medicine positron emission tomography (PET) or single-photon emission computed tomography (SPECT) imaging diagnosis of CSPG4 / NG2 positive tumors or CSPG4 / NG2 positive lesions, such as autoimmune diseases and cardiovascular and cerebrovascular diseases, thereby realizing early diagnosis and efficacy evaluation of malignant tumors.

This provides an improved method for treating malignant tumors in human patients. [Solution] A method comprising administering a therapeutically effective dose of a LAG-3 inhibitor; a PD-1 pathway inhibitor; and an immunotherapy agent.

This invention provides a hypoxia-mediated mechanism of malignant tumor formation, a treatment simulation method, and a system, relating to the field of biomathematical modeling technology. The method includes: dividing the tumor into a core region and a peripheral region, defining the core differences between the two regions in their microenvironmental composition, and forming a conceptual interaction network; establishing a state variable system centered on the number of tumor cells, constructing a mathematical model integrating tumor core-periphery heterogeneity, hypoxia-mediated processes, and immunosuppression cycles; solving the mathematical model, calculating the changes of each state variable over time under different initial conditions or intervention parameters, and outputting simulation results characterizing tumor growth and the state of the immune microenvironment; this invention, through the multi-level regulation of cell proliferation, immunosuppression cycles, and angiogenesis signals by oxygen concentration gradients, more realistically reproduces the spatial heterogeneous growth dynamics of solid tumors in vivo, and simulates the formation and maintenance mechanism of a strong immunosuppressive state in the tumor core region.

This invention discloses a methylation marker for the differential diagnosis of malignant and benign breast tumors. The invention provides the application of the methylated SH3PXD2B gene as a marker in product preparation; the product is used for at least one of the following purposes: (1) distinguishing between benign and malignant breast tumors; (2) distinguishing between benign breast tumors and different subtypes or stages of malignant breast tumors; (3) distinguishing between different subtypes or stages of malignant breast tumors. This invention has significant scientific and clinical application value for differentiating between benign and malignant breast tumors, different subtypes or stages of malignant breast tumors, and guiding the development of reasonable clinical treatment plans.

The invention discloses a 2-amino-4-anilino pyrimidine compound as well as a preparation method and application of the 2-amino-4-anilino pyrimidine compound. The compound has a strong inhibition effect on EGFR (epidermal growth factor receptor) gene mutation targets and c-MET and has a strong inhibition effect on osimertinib drug-resistant cells; and the compound can inhibit proliferation of various tumor cells, and provides excellent application prospects for treatment of EGFR gene mutation and MET amplified malignant tumors.

Disclosed is the use of a composition comprising a TET pathway inhibitor and a ferroptosis inducer in the manufacture of a medicament for the treatment of malignant tumors. It is found that TET1 up-regulates expression of a ferroptosis key regulation gene GCH1 through an NF [kappa] B signal, promotes synthesis of BH4, activates a GPX4 non-dependent pathway, and plays a key hub role in controlling ferroptosis sensitivity. Through combined use of TET pathway inhibitors (including a TET inhibitor and a BH4 synthesis inhibitor), the sensitivity of tumor cells to the ferroptosis inducer can be significantly improved, and the in-vivo use dosage of the ferroptosis inducer is reduced to 1% (1 mg / kg) of the conventional treatment dosage. The composition of the TET pathway inhibitor and the ferroptosis inducer, provided by the invention, can be used for remarkably improving the ferroptosis induction curative effect of various malignant tumors, particularly ferroptosis insensitive tumors, and enhancing the safety and universality of ferroptosis induction treatment.

The invention discloses a 2-amino-4-aromatic heterocyclic-1, 3, 5-triazine compound and application thereof, and the 2-amino-4-aromatic heterocyclic-1, 3, 5-triazine compound has the following structural general formula as shown in the specification, wherein W, X, Y and Z are independently selected from carbon or nitrogen. The 2-amino-4-aromatic heterocyclic-1, 3, 5-triazine compound designed and synthesized by the invention is a novel NF-kappa B induced kinase (NIK) inhibitor and is suitable for drug development taking INIK as a target spot, and the obtained drug can be used for treating malignant tumors such as leukemia, multiple myeloma glioma and the like.

The present invention relates to systems and methods for classification of cancer from gene expression input data. The method including: receiving a training dataset including nucleic acid data points from one or more samples; identifying classes in the training dataset including performing recursive clustering by, at each successive iteration, performing a search to identify clusters based on similarity, wherein each class of the classes is associated with a tumor; training a machine learning model to associate the nucleic acid data points of the training dataset with the identified classes; receiving the gene expression input data for classification; classifying, using the trained machine learning model, the gene expression input data as one or more of the identified classes; and outputting the classification of the gene expression input data.

The present invention disclosures a novel purine derivatives represented by formula (I) or a pharmaceutically acceptable salt thereof, intermediate and application thereof inpreparation of a medicament for treating or preventing a cancer. This compound is a novel PI3K inhibitor with an excellent inhibitory activity, and may be useful for treating a variety of malignant tumors.

The present invention features fratricide resistant modified immune cells (e.g., T- or NK-cells) having enhanced anti-neoplasia activity and methods for producing and using the same. Methods of treating neoplasia (e.g., T- or NK-cell malignancies) using fratricide resistant modified immune cells are also provided.

The present invention provides an antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of L718X mutation in exon 18 and L792X mutation in exon 20, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising(S)—N-(4-amino-6-methyl-5-(quinolin-3-yl)-8.9-dihydropyrimido[5.4-b]indolizin-8-yl)acrylamide (Compound (A)) or a salt thereof.

A gene delivery system and applications thereof in the technical field of biological medicines that is particularly useful in the preparation of drugs for treatment of tumors are disclosed. The gene delivery system and applications relate to technology for inducing the differentiation of malignant tumor cells into mature cells, in which regulating the expression of HNF4 alpha protein in the malignant tumor cells using messenger ribonucleic acid, the malignant phenotype of the malignant solid tumor cells is inhibited, and the effective treatment of the malignant solid tumors is achieved. The gene delivery system and applications are therefore applicable to a method of preparing a drug for treating malignant solid tumors and to a method of treating a patient having a malignant solid tumor.

The invention provides a medicine for treating a biliary tract tumor. The medicine comprises donepezil. After corresponding treatment, the apoptosis process of cancer cells can be obviously observed in a culture solution containing donepezil, which proves that the cancer cells on the biliary tract tumor organoid and cell line have no toxic or side effect. Donepezil can effectively inhibit proliferation of biliary tract tumor organs and promote apoptosis of the biliary tract tumor organs and cell lines, and has the prospect of treating biliary tract malignant tumors.

The invention belongs to the field of biological medicines, and particularly relates to a medicine for treating meningeal metastasis of malignant tumors with NTRK and / or ROS1 mutations and a preparation method, and the medicine is a freeze-dried powder preparation or injection for subarachnoid space injection of NTRK / ROS1-TKIs. The invention also provides an application of the NTRK / ROS1-TKIs in preparation of a medicine for treating meningeal metastasis of malignant tumors with NTRK and / or ROS1 mutation. The prepared NTRK / ROS1-TKIs injection can be directly injected into the subarachnoid space of a patient, the drug concentration in cerebrospinal fluid of the patient is greatly improved, the cerebrospinal fluid / plasma concentration ratio can reach 20 times or more, the problem of insufficient dosage caused by the blood-brain barrier after the targeted drug is orally taken can be completely solved, and the drug has the advantages of fast effect taking, no toxic or side effect and no toxic or side effect. The treatment effect on meningeal metastasis of malignant tumors such as lung cancer can be obviously improved.

FIELD: oncology.SUBSTANCE: used to treat malignant embryonic tumors. The method involves pharmacological inhibition of factors that support tumor growth. A progesterone receptor antagonist is administered and immunological activation of the body's response against progesterone-induced blocking factor (PIBF), placental growth factor (PIGF) and trophoblastic β 1-glycoprotein.EFFECT: increased treatment reliability due to a comprehensive and selective effect on the tumor, simultaneous influence on both the primary tumor site and metastases, a reduction in the likelihood of relapse due to the destruction of the tumor vascular network, and a reduction in the overall toxic load on the patient's body during treatment.7 cl, 1 tbl, 5 ex

The application discloses damaged mitochondria as a malignant tumor metastasis prediction marker, and an application and detection system thereof, and is used for solving the problems of lacking specific prediction indexes and efficient and feasible prediction means for predicting malignant tumor metastasis in the prior art. The application rapidly enriches mitochondria from a to-be-detected plasma sample, detects the concentration of the prediction marker damaged mitochondria, and predicts the malignant tumor metastasis risk of a patient corresponding to the to-be-detected plasma sample based on the concentration of the prediction marker damaged mitochondria, so that whether the tumor patient will have metastasis in the future can be simply, rapidly and accurately predicted.

The invention relates to the field of medicines, in particular to a compound 5-hydroxy-6-bromo-12-methyl-10, 11, 12, 13-tetrahydro-1H-azepine ketone [5, 4, 3-cd] indole applied to a tyrosine kinase C-kit receptor inhibitor or a malignant tumor medicine, and the structural formula of the compound is shown in the specification. The compound disclosed by the invention has a good inhibition effect on a tyrosine kinase C-kit receptor and is suitable for preparing medicines for treating malignant tumors.

The application discloses application of a small-molecule compound LZ-A4 in preparation of a preparation or a medicine for treating malignant tumors. 19 H 11 Cl2N3O3S, which can promote LGMN degradation in malignant tumor cells, inhibit tumor cell proliferation, and inhibit macrophage polarization to M2 type. The application proves through research on a colorectal cancer mouse transplanted tumor model that LZ-A4 alone can effectively inhibit the progression of colorectal cancer, and after being combined with a colorectal cancer first-line chemotherapy medicine oxaliplatin, the tumor volume can be further reduced. Meanwhile, LZ-A4 can inhibit M2 type polarization of macrophages in a tumor microenvironment in vivo, promote infiltration of cytotoxic T cells, reshape the tumor microenvironment, and activate anti-tumor immunity. In addition, A4 performs well in terms of toxic side effects, and after being combined with the chemotherapy medicine, the mouse weight is not further reduced.